Insulin degludec/insulin aspart

From WikiMD's WELLNESSPEDIA

Combination insulin medication

Insulin degludec/insulin aspart



Trade names Ryzodeg





Routes Subcutaneous injection
Pregnancy category C





Legal status Rx-only

















Insulin degludec/insulin aspart is a combination medication used in the management of diabetes mellitus. It is a mixture of two types of insulin: insulin degludec, a long-acting insulin, and insulin aspart, a rapid-acting insulin. This combination is marketed under the brand name Ryzodeg.

Medical uses[edit]

Insulin degludec/insulin aspart is indicated for the treatment of type 1 diabetes and type 2 diabetes in adults. It helps to control blood glucose levels by providing both basal and prandial insulin coverage.

Mechanism of action[edit]

The combination of insulin degludec and insulin aspart works by mimicking the body's natural pattern of insulin release. Insulin degludec provides a steady, long-lasting insulin level, while insulin aspart offers a rapid onset of action to manage blood sugar spikes after meals.

Administration[edit]

The medication is administered via subcutaneous injection. The dosing schedule is typically individualized based on the patient's needs, blood glucose monitoring results, and glycemic control goals.

Side effects[edit]

Common side effects include hypoglycemia, allergic reactions, and injection site reactions. Patients should be monitored for signs of low blood sugar and other adverse effects.

See also[edit]

References[edit]


External links[edit]

  • Insulin degludec/insulin aspart on WikiMD

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.